Symbols / NKGN
NKGN Chart
About
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease; and SNK02, which consists of an allogenic NK cell therapy that has completed Phase 1 trial and a HER2-CAR NK cell therapy candidate in pre-clinical trial to treat refractory solid tumors. It has a strategic partnership with HekaBio K.K., a Japan-based healthcare platform, to develop, conduct clinical trials, obtain regulatory approvals, manufacture, and commercialize the company's autologous NK cell therapy product candidates for central nervous system and autoimmune conditions in Japan. The company also has a license agreement with NKMAX Co., Ltd. for the research and development of its NK cell program. NKGen Biotech, Inc. was founded in 2017 and is headquartered in Santa Ana, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.84M |
| Enterprise Value | 46.02M | Income | -23.55M | Sales | — |
| Book/sh | -0.98 | Cash/sh | 6000.00 | Dividend Yield | — |
| Payout | 0.00% | Employees | 26 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | -0.06 | P/C | — |
| EV/EBITDA | -2.02 | EV/Sales | — | Quick Ratio | 0.00 |
| Current Ratio | 0.05 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.33 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | -93.33% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 130.60M |
| Shs Float | 65.51M | Short Float | 5.53% | Short Ratio | 0.38 |
| Short Interest | — | 52W High | 0.59 | 52W Low | 0.00 |
| Beta | 0.95 | Avg Volume | 5.68K | Volume | 200.00 |
| Target Price | — | Recom | None | Prev Close | $0.06 |
| Price | $0.06 | Change | 0.00% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.06
Latest analyst target
3. DCF / Fair value
$-2.89
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.06
Low
—
High
—
Mean
—
- Form 10-K Filed Oct 8, 2025 — NKGen Biotech clarifies OTC Expert Market quotes; Common Stock remains tradable - Stock Titan hu, 09 Oct 2025 07
- $16.9M Strategic Acquisition: NKGen Biotech Gains Full Control of NK Cell Therapy Manufacturing & IP Portfolio - Stock Titan ue, 09 Sep 2025 07
- NKGen Biotech Secures Additional Funding via Note Amendment - TipRanks Mon, 26 Jan 2026 08
- NKGen Biotech, Inc. to Transition from the Nasdaq Global Market to OTC Markets; Reverse Stock Split will not be Implemented - Yahoo Finance ue, 04 Mar 2025 08
- Leading Alzheimer’s doctor joins NKGen on NK cell therapy - Stock Titan hu, 22 Jan 2026 08
- NKGen Biotech Expands Debt Financing Through Note Amendment - TipRanks Fri, 16 Jan 2026 08
- Barclays Just Raised Its Price Target on Intuitive Surgical (ISRG) Stock - InvestorPlace hu, 18 Jul 2024 07
- NKGen’s Volatility Tied to South Korea - Orange County Business Journal Mon, 17 Jun 2024 07
- What's Going On With Nano-Cap NKGen Biotech Stock On Monday? - Yahoo Finance Mon, 22 Apr 2024 07
- Groundbreaking NK Cell Therapy Data for Alzheimer's: 6-Month Results to be Revealed at Major Conference - Stock Titan ue, 25 Mar 2025 07
- NKGN - NKGen Biotech Inc Latest Stock News & Market Updates - Stock Titan Mon, 02 Oct 2023 21
- Groundbreaking Brain Barrier-Crossing Treatment Starts in Frontotemporal Dementia Patient - Will NK Cells Change Neurology? - Stock Titan Fri, 21 Feb 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 19669552 | 5605822 | — | Purchase at price 0.28 per share. | CFIC-2015 NV FAMILY INVESTMENTS LLC., | Beneficial Owner of more than 10% of a Class of Security | — | 2025-05-27 00:00:00 | D |
| 1 | 20849725 | 2650000 | — | Purchase at price 0.13 per share. | SONG PAUL Y | Chief Executive Officer | — | 2025-05-05 00:00:00 | D |
Financials
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | -5.90M | 0.00 | 0.00 | |
| TaxRateForCalcs | 0.21 | 0.21 | 0.27 | |
| NormalizedEBITDA | -52.90M | -23.23M | -20.70M | |
| TotalUnusualItems | -28.10M | 0.00 | ||
| TotalUnusualItemsExcludingGoodwill | -28.10M | 0.00 | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -82.95M | -26.75M | -23.27M | |
| ReconciledDepreciation | 1.20M | 1.21M | 1.24M | |
| ReconciledCostOfRevenue | 0.00 | 18.00K | 30.00K | |
| EBITDA | -81.00M | -23.23M | -20.70M | |
| EBIT | -82.20M | -24.44M | -21.95M | |
| NetInterestIncome | -25.22M | -2.31M | -1.31M | |
| InterestExpense | 745.00K | 2.31M | 1.31M | |
| NormalizedIncome | -60.75M | -26.75M | -23.27M | |
| NetIncomeFromContinuingAndDiscontinuedOperation | -82.95M | -26.75M | -23.27M | |
| TotalExpenses | 29.75M | 24.42M | 22.29M | |
| TotalOperatingIncomeAsReported | -29.75M | -24.35M | -21.86M | |
| DilutedAverageShares | 28.83M | 15.43M | 32.60M | 32.60M |
| BasicAverageShares | 28.83M | 15.43M | 32.60M | 32.60M |
| DilutedEPS | -1.54 | -5.38 | -0.82 | -0.71 |
| BasicEPS | -1.54 | -5.38 | -0.82 | -0.71 |
| DilutedNIAvailtoComStockholders | -82.95M | -26.75M | -23.27M | |
| NetIncomeCommonStockholders | -82.95M | -26.75M | -23.27M | |
| NetIncome | -82.95M | -26.75M | -23.27M | |
| NetIncomeIncludingNoncontrollingInterests | -82.95M | -26.75M | -23.27M | |
| NetIncomeContinuousOperations | -82.95M | -26.75M | -23.27M | |
| TaxProvision | 7.00K | 7.00K | 5.00K | |
| PretaxIncome | -82.95M | -26.75M | -23.26M | |
| OtherIncomeExpense | -27.98M | -95.00K | -84.00K | |
| OtherNonOperatingIncomeExpenses | 120.00K | -95.00K | -84.00K | |
| SpecialIncomeCharges | -3.33M | 0.00 | ||
| RestructuringAndMergernAcquisition | 3.33M | 0.00 | ||
| GainOnSaleOfSecurity | -24.77M | |||
| NetNonOperatingInterestIncomeExpense | -25.22M | -2.31M | -1.31M | |
| InterestExpenseNonOperating | 745.00K | 2.31M | 1.31M | |
| OperatingIncome | -29.75M | -24.35M | -21.86M | |
| OperatingExpense | 29.75M | 24.41M | 22.26M | |
| ResearchAndDevelopment | 15.67M | 16.75M | 14.67M | |
| SellingGeneralAndAdministration | 14.08M | 7.66M | 7.58M | |
| GeneralAndAdministrativeExpense | 14.08M | 7.66M | 7.58M | |
| OtherGandA | 14.08M | 7.66M | 7.58M | |
| GrossProfit | 0.00 | 59.00K | 396.00K | |
| CostOfRevenue | 0.00 | 18.00K | 30.00K | |
| TotalRevenue | 0.00 | 77.00K | 426.00K | |
| OperatingRevenue | 0.00 | 77.00K | 426.00K |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| OrdinarySharesNumber | 21.89M | 21.89M | 21.89M |
| ShareIssued | 21.89M | 21.89M | 21.89M |
| NetDebt | 19.89M | 11.54M | 50.80M |
| TotalDebt | 19.92M | 12.03M | 51.97M |
| TangibleBookValue | -58.78M | 1.47M | -38.14M |
| InvestedCapital | -38.77M | 13.22M | 13.10M |
| WorkingCapital | -37.52M | -14.39M | -55.13M |
| NetTangibleAssets | -58.78M | 1.47M | -38.14M |
| CapitalLeaseObligations | 0.00 | 379.00K | 818.00K |
| CommonStockEquity | -58.69M | 1.56M | -38.05M |
| TotalCapitalization | -48.76M | 1.56M | -38.05M |
| TotalEquityGrossMinorityInterest | -58.69M | 1.56M | -38.05M |
| StockholdersEquity | -58.69M | 1.56M | -38.05M |
| OtherEquityInterest | -18.29M | ||
| RetainedEarnings | -162.13M | -79.18M | -52.42M |
| AdditionalPaidInCapital | 121.73M | 80.74M | 14.36M |
| CapitalStock | 2.00K | 1.00K | 14.00K |
| CommonStock | 2.00K | 1.00K | 14.00K |
| TotalLiabilitiesNetMinorityInterest | 75.17M | 14.77M | 56.12M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 35.72M | 26.00K | 379.00K |
| DerivativeProductLiabilities | 25.76M | 0.00 | |
| NonCurrentDeferredLiabilities | 33.00K | 26.00K | 19.00K |
| NonCurrentDeferredTaxesLiabilities | 33.00K | 26.00K | 19.00K |
| LongTermDebtAndCapitalLeaseObligation | 9.93M | 0.00 | 360.00K |
| LongTermCapitalLeaseObligation | 0.00 | 360.00K | |
| LongTermDebt | 9.93M | ||
| CurrentLiabilities | 39.45M | 14.74M | 55.74M |
| OtherCurrentLiabilities | 15.86M | 55.00K | 63.00K |
| CurrentDebtAndCapitalLeaseObligation | 9.99M | 12.03M | 51.61M |
| CurrentCapitalLeaseObligation | 0.00 | 379.00K | 458.00K |
| CurrentDebt | 9.99M | 11.65M | 51.15M |
| OtherCurrentBorrowings | 5.00M | 11.65M | 51.15M |
| LineOfCredit | 4.99M | 0.00 | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 911.00K | 291.00K | 240.00K |
| PayablesAndAccruedExpenses | 12.69M | 2.36M | 3.83M |
| CurrentAccruedExpenses | 1.36M | 1.36M | 248.00K |
| Payables | 11.33M | 1.00M | 3.58M |
| OtherPayable | 84.00K | 27.00K | |
| DuetoRelatedPartiesCurrent | 202.00K | 0.00 | 1.87M |
| AccountsPayable | 11.04M | 975.00K | 1.71M |
| TotalAssets | 16.48M | 16.33M | 18.07M |
| TotalNonCurrentAssets | 14.55M | 15.98M | 17.46M |
| GoodwillAndOtherIntangibleAssets | 92.00K | 97.00K | 89.00K |
| OtherIntangibleAssets | 92.00K | 97.00K | 89.00K |
| NetPPE | 14.46M | 15.88M | 17.37M |
| AccumulatedDepreciation | -3.83M | -2.69M | -1.53M |
| GrossPPE | 18.28M | 18.57M | 18.90M |
| Leases | 52.00K | 52.00K | 52.00K |
| OtherProperties | 4.00M | 4.37M | 4.71M |
| MachineryFurnitureEquipment | 878.00K | 806.00K | 806.00K |
| BuildingsAndImprovements | 8.32M | 8.32M | 8.31M |
| LandAndImprovements | 5.03M | 5.03M | 5.03M |
| Properties | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 1.93M | 350.00K | 612.00K |
| OtherCurrentAssets | 63.00K | 4.00K | 22.00K |
| RestrictedCash | 250.00K | 0.00 | |
| PrepaidAssets | 1.56M | 133.00K | 172.00K |
| Receivables | 26.00K | 96.00K | 67.00K |
| OtherReceivables | 26.00K | 67.00K | 67.00K |
| AccountsReceivable | 0.00 | 29.00K | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 26.00K | 117.00K | 351.00K |
| CashAndCashEquivalents | 26.00K | 117.00K | 351.00K |
| Line Item | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| FreeCashFlow | -22.00M | -22.72M | -20.01M |
| RepaymentOfDebt | -300.00K | -675.00K | -404.00K |
| IssuanceOfDebt | 26.51M | 23.00M | 20.50M |
| IssuanceOfCapitalStock | 1.67M | 0.00 | 63.00K |
| CapitalExpenditure | -48.00K | -163.00K | -459.00K |
| InterestPaidSupplementalData | 241.00K | 35.00K | |
| EndCashPosition | 276.00K | 117.00K | 351.00K |
| BeginningCashPosition | 117.00K | 351.00K | 199.00K |
| ChangesInCash | 159.00K | -234.00K | 152.00K |
| FinancingCashFlow | 22.16M | 22.49M | 20.16M |
| CashFlowFromContinuingFinancingActivities | 22.16M | 22.49M | 20.16M |
| NetOtherFinancingCharges | -15.94M | ||
| ProceedsFromStockOptionExercised | 10.22M | 161.00K | 63.00K |
| NetCommonStockIssuance | 1.67M | 0.00 | 63.00K |
| CommonStockIssuance | 1.67M | 0.00 | 63.00K |
| NetIssuancePaymentsOfDebt | 26.21M | 22.32M | 20.10M |
| NetShortTermDebtIssuance | 9.99M | 23.00M | 20.50M |
| ShortTermDebtPayments | -300.00K | 0.00 | -404.00K |
| ShortTermDebtIssuance | 10.29M | 23.00M | 20.50M |
| NetLongTermDebtIssuance | 16.21M | -675.00K | -404.00K |
| LongTermDebtPayments | 0.00 | -675.00K | -404.00K |
| LongTermDebtIssuance | 16.21M | 0.00 | |
| InvestingCashFlow | -48.00K | -163.00K | -459.00K |
| CashFlowFromContinuingInvestingActivities | -48.00K | -163.00K | -459.00K |
| NetPPEPurchaseAndSale | 0.00 | -101.00K | -403.00K |
| PurchaseOfPPE | 0.00 | -101.00K | -403.00K |
| CapitalExpenditureReported | -48.00K | -62.00K | -56.00K |
| OperatingCashFlow | -21.95M | -22.56M | -19.55M |
| CashFlowFromContinuingOperatingActivities | -21.95M | -22.56M | -19.55M |
| ChangeInWorkingCapital | 2.23M | 30.00K | 932.00K |
| ChangeInOtherWorkingCapital | -14.00K | -4.00K | 26.00K |
| ChangeInOtherCurrentLiabilities | -379.00K | -437.00K | -116.00K |
| ChangeInPayablesAndAccruedExpense | 3.99M | 443.00K | 959.00K |
| ChangeInPrepaidAssets | -1.40M | 57.00K | -48.00K |
| ChangeInReceivables | 29.00K | -29.00K | 111.00K |
| ChangesInAccountReceivables | 29.00K | -29.00K | 111.00K |
| OtherNonCashItems | 4.20M | 2.71M | 1.30M |
| StockBasedCompensation | 4.13M | 69.00K | 93.00K |
| UnrealizedGainLossOnInvestmentSecurities | 24.33M | 177.00K | 143.00K |
| DepreciationAmortizationDepletion | 1.20M | 1.21M | 1.24M |
| DepreciationAndAmortization | 1.20M | 1.21M | 1.24M |
| Depreciation | 1.65M | 1.24M | |
| OperatingGainsLosses | 24.92M | ||
| GainLossOnInvestmentSecurities | 24.92M | ||
| NetIncomeFromContinuingOperations | -82.95M | -26.75M | -23.27M |
SEC Filings
No SEC filings found for this symbol (may be non-US or ticker not in SEC index).
Public Trades for NKGN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|